German Christopher Paul 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Aug 14, 2025
Insider Transaction Report
Form 4
German Christopher Paul
Corporate Controller & CAO
Transactions
- Sale
Common Stock
2025-08-12$95.00/sh−1,500$142,500→ 922 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-08-12−500→ 4,050 totalExercise: $49.23Exp: 2034-02-15→ Common Stock (500 underlying) - Exercise/Conversion
Common Stock
2025-08-12$17.97/sh+1,000$17,970→ 1,922 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-08-12−1,000→ 5,231 totalExercise: $17.97Exp: 2033-04-03→ Common Stock (1,000 underlying) - Exercise/Conversion
Common Stock
2025-08-12$49.23/sh+500$24,615→ 1,422 total
Footnotes (3)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025.
- [F2]The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.
- [F3]The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.